SG1827

DRUG2 trials

Sponsors

Hangzhou Sumgen Biotech Co., Ltd.

Conditions

Advanced Solid Tumors

Phase 1

An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors

CompletedNCT06076291

Hangzhou Sumgen Biotech Co., Ltd.Advanced Solid Tumors

Start: 2023-09-27End: 2026-03-18Updated: 2026-09-04

An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors

Not yet recruitingNCT07774611

Hangzhou Sumgen Biotech Co., Ltd.Advanced Solid Tumors

Start: 2026-09-22End: 2028-12-31Target: 180Updated: 2026-08-19